Morningstar‘s Stock Analysis BSLN
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile BSLN
Basilea Pharmaceutica Ltd is a biotechnology company that focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections, and oncology. The company aims to develop drugs in order to target the medical challenge of resistance and non-response to current treatment options. The company's research strategy integrates the areas of genomics, cell biology, medicinal chemistry, and pharmacology. Its commercial product comprises of Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections.
Basel, 4058, Switzerland